Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
May 2, 2017 BOSTON, May 02, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immun...
PDF
May 1, 2017 — Advancing Plans to Initiate Pivotal Study for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer — - Company to Host Conference Call Today at 4:30 p.m. ET - BOSTON, ...
PDF
Apr 24, 2017 BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, May 1, 2017 at 4:30 p.m. ET to provide a corporate update and discuss financial results for...
PDF
Apr 20, 2017 BOSTON, April 20, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or ...
PDF
Apr 3, 2017 GERMANTOWN, Md. and BOSTON, April 03, 2017 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ZIOPHARM Oncology (NASDAQ:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Merck KGaA, Darm...
PDF
Mar 27, 2017 BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy product candidate, Ad-RTS-hIL-...
PDF
Mar 27, 2017 BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the appointment of Amy Trevvett as Vice President of Investor Relations and Corporate Communications. "Amy's background in investor relati...
PDF
Feb 16, 2017 - Company to Webcast Corporate Update Thursday, February 23, at the 2017 RBC Global Healthcare Conference - BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced financial res...
PDF
Jan 31, 2017 — First Patient Treated with Non-viral Sleeping Beauty Modified CAR-T Cells Produced in 2 Weeks— Anticipate Phase 1 Clinical Trial Launch in 2017 with Administration of Sleeping Beauty CAR-T Cells Produced within 2 Days— Shortened Process Delivers Genetically Mo...
PDF
Jan 10, 2017 BOSTON, MA and GERMANTOWN, MD – January 10, 2017 – ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the signing of a Co...
PDF
Page: FirstPrevious
2
... NextLast